2022
Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
Brothers S, DiDomizio E, Nichols L, Brooks R, Villanueva M. Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment. AIDS And Behavior 2022, 27: 119-133. PMID: 35776253, PMCID: PMC9663279, DOI: 10.1007/s10461-022-03749-8.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsHIV/HCVDAA treatmentHCV treatmentHIV/HCV Co-infectionDAA treatment uptakeHCV Co-InfectionPatient-level barriersHCV diseaseAdherence supportHepatitis CActing antiviralsTreatment uptakeCo-InfectionTreatment barriersHCVTreatmentPWHAntiviralsQualitative interviewsHIVDiseaseDiagnosisPersonsUptakeRapidly enlarging pulmonary mass due to immune reconstitution inflammatory syndrome (IRIS) in an immunocompetent host with pulmonary Cryptococcus neoformans.
Tucker M, Sheikh AM, Villanueva MS. Rapidly enlarging pulmonary mass due to immune reconstitution inflammatory syndrome (IRIS) in an immunocompetent host with pulmonary Cryptococcus neoformans. BMJ Case Reports 2022, 15: e247495. PMID: 35351746, PMCID: PMC8966528, DOI: 10.1136/bcr-2021-247495.Peer-Reviewed Case Reports and Technical NotesConceptsImmune reconstitution inflammatory syndromeReconstitution inflammatory syndromeInflammatory syndromePulmonary massImmunocompetent hostsInitial induction courseLarge pulmonary massWeeks of fluconazoleLiposomal amphotericin BCritical vascular structuresInduction therapyImmunocompetent manInduction courseSecond courseAmphotericin BCryptococcus neoformansVascular structuresSignificant decreaseCryptococcomaSyndromeWeeksPrednisoneTherapyFlucytosineDisease
2021
Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study
Virata MD, Shenoi SV, Ladines-Lim J, Villanueva MS, Barakat LA. Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study. PLOS ONE 2021, 16: e0260251. PMID: 34851963, PMCID: PMC8635326, DOI: 10.1371/journal.pone.0260251.Peer-Reviewed Original ResearchConceptsOne-year retrospective cohort studyCohort of PWHNon-communicable comorbiditiesPredictors of hospitalizationRetrospective cohort studyChronic lung diseaseLikelihood of hospitalizationSingle-site experienceCOVID-19 infectionNon-communicable diseasesOutcomes of peopleCohort studyHIV diseaseOverall mortalityClinical outcomesLung diseaseCardiovascular diseaseHospitalizationCumulative burdenHIVLater timeframeDiseaseEarly epidemicPWHOutcomes
2020
Confronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response
Edelman EJ, Aoun-Barakat L, Villanueva M, Friedland G. Confronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response. AIDS And Behavior 2020, 24: 1977-1979. PMID: 32399798, PMCID: PMC7215127, DOI: 10.1007/s10461-020-02908-z.Peer-Reviewed Original Research
2018
Fatal cryptococcal meningitis in an AIDS patient complicated with immune reconstitution syndrome refractory to prolonged amphotericin B treatment
Bandaranayake TD, Ogbuagu OE, Mahajan A, Vortmeyer AO, Villanueva MS. Fatal cryptococcal meningitis in an AIDS patient complicated with immune reconstitution syndrome refractory to prolonged amphotericin B treatment. International Journal Of STD & AIDS 2018, 29: 1250-1254. PMID: 29749873, DOI: 10.1177/0956462418773219.Peer-Reviewed Case Reports and Technical NotesConceptsCentral nervous system diseaseNervous system diseasesCryptococcal meningitisSystem diseasesSevere central nervous system diseaseFatal cryptococcal meningitisLiposomal amphotericin BAmphotericin B treatmentImmune recoveryPatient refractoryAntiretroviral therapyTherapeutic challengeTreatment failureAIDS patientsCystic lesionsFatal casesTreatment approachesMeningitisAmphotericin BC. neoformansMultiple coursesCryptococcus neoformansPatientsB treatmentDisease